US FDA proposes to exclude Semaglutide (NOVOB DC), Tirzepatide (LLY), and Liraglutide (NOVOB DC) on 503B bulks list

The FDA's proposal to exclude Semaglutide, Tirzepatide, and Liraglutide from the 503B bulks list could impact the competitive landscape for these drugs in the compounding pharmacy market.

Newsquawk StaffPublished On the live feed at 12 more headlines followed before this page went public
Newsquawk headlinesUTC

Some US House GOP hardliners are privately encouraging Senate Republican hardliners to block the Senate’s 45-day FISA extension, according to Politico citing sources

Steve Cohen relinquishes President Title at his Point72 hedge fund, Bloomberg reports

US FDA proposes to exclude Semaglutide (NOVOB DC), Tirzepatide (LLY), and Liraglutide (NOVOB DC) on 503B bulks list

White House posts "There will never be a deal unless [Iran] agrees that THERE WILL BE NO NUCLEAR WEAPONS"

ECB President Lagarde (Q&A) says there is a range of data ECB will be monitoring in the coming weeks; again notes uncertainties

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

This decision might lead to heightened scrutiny on these products and affect their availability or pricing dynamics, which could, in turn, influence the stock performance of Eli Lilly and Novo Nordisk in both the short and medium term.

Related headlines

The whole workspace, free to try.

Try it free